October 28, 2026
The information on this site is not intended to take the place of your doctor or other healthcare professionals. It is a resource to help you make the best decisions and get the most from the medical services available to you. A licensed physician should be consulted for diagnosis and treatment of all medical conditions.
On Oct. 7, 2026, Biotest AG initiated a voluntary withdrawal of one lot of Yimmugo® (immune globulin intravenous, human-dira) 10% liquid. The withdrawal was a precaution after an increased rate of allergic or hypersensitivity-type reactions with this lot, including a small number of medically significant reactions. Hypersensitivity and anaphylactic/anaphylactoid reactions are known risks of immune globulin products. Yimmugo is FDA-approved for the treatment of primary humoral immunodeficiency (PI) in patients 2 years of age and older.
Last updated: October 28, 2026